| (AbbVie) M24-108 | A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT05650632 |
| (Amgen) 20190360 / Golden Gate | Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) | Dr Michael Radford | Suspended/On hold | NCT04994717 |
| (AstraZeneca) D7230C00001 | A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT06106945 |
| (BeiGene) BGB-3111-308 / MAHOGANY | A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Dr Gwynivere Davies | Open to recruitment | NCT05100862 |
| (CCTG) HD.11 | A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma | Dr Amaris Balitsky | Open to recruitment | NCT05180097 |
| (CCTG) LY.17 | A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Dr Graeme Fraser | Suspended/On hold | NCT02436707 |
| (CCTG) MY.13 | A PHASE III NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL OF FIXED DURATION VERSUS CONTINUOUS DARATUMUMAB AMONG TRANSPLANT INELIGIBLE OLDER ADULTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA | Dr Hira Mian | Open to recruitment | NCT06182774 |
| (CCTG) SC.26 / EASE | Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia | Dr Alejandro Garcia-Horton | Open to recruitment | NCT04224974 |
| (EMN) EMN28 / 68284528MMY3005 / CARTITUDE-6 | A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible | Dr Mohammed Aljama | Open to recruitment | NCT05257083 |
| (Janssen) 64407564MMY3009 / MonumenTAL-6 | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P),Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of EitherElotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, andDexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | Dr Hira Mian | Suspended/On hold | NCT06208150 |
| (Pfizer) C1071007 / MAGNETISMM-7 | A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION | Dr Mohammed Aljama | Open to recruitment | NCT05317416 |
Find a Trial
Contact Us